Debora Fumagalli

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Sherene Loi, Stefan Michiels, Roberto Salgado et al. · Annals of Oncology · 2014 · 1.3K citations

Breast Oncology, Cancer Immunosurveillance, Medicine +10

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos et al. · The Lancet Oncology · 2019 · 464 citations

Breast Oncology, Oncology, Pharmacology +8

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Journal of Clinical Oncology · 2021 · 346 citations · Full text

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart, Laura van ‘t Veer, Coralie Poncet et al. · The Lancet Oncology · 2021 · 336 citations · Full text

Breast Oncology, Early Breast Cancer, Medicine +11